Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SUBA-itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses: a Multi-center, Open-label Comparative Trial

Next Previous
Trial Profile

SUBA-itraconazole Versus Conventional Itraconazole in the Treatment of Endemic Mycoses: a Multi-center, Open-label Comparative Trial

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 26 Oct 2018

At a glance

  • Drugs Itraconazole (Primary)
  • Indications Mycoses
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

    • Most Recent Events

    • 18 Oct 2018 Planned End Date changed from 1 Dec 2019 to 31 Dec 2019.
    • 18 Oct 2018 Planned primary completion date changed from 1 Dec 2019 to 30 May 2019.
    • 17 Aug 2018 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top